Fablyn nedsatte signifikant forekomsten af nye radiografisk verificerede rygsøjlefrakturer (undtagen forværring af tidligere frakturer) fra 9, 3% for placebo til 5, 6% for Fablyn (relativ reduktion af risiko = 41%, p < 0, 0001).
FABLYN significantly decreased the incidence of new radiographic vertebral fractures (excluding worsening of previous fractures) from 9.3% for placebo to 5.6% for FABLYN (relative risk reduction = 41%, p < 0.0001).